Neurologix to Trade With New Ticker Symbol NLGX.Business Editors FORT LEE, N.J.--(BUSINESS WIRE)--Feb. 11, 2004 Neurologix, Inc., a developer of proprietary gene therapies for treating central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency , today announced that beginning tomorrow, Thursday, February 12, its stock will trade on the OTC Bulletin Board OTC Bulletin Board An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system. under the ticker symbol NLGX. The receipt of a new ticker symbol relates to the recently announced completion of its reverse merger with a wholly-owned subsidiary of Change Technology Partners, Inc. ("CTP CTP (cytidine triphosphate): see cytosine. (1) (Computer-To-Plate) The production of printing plates directly from the computer without requiring film as an intermediate step. ") which previously traded on the OTC Bulletin Board under the ticker symbol CTPI CTPI Champion Tree Project International . At a special meeting held on February 9, 2004, CTP shareholders agreed to the previously-announced merger of the two companies. As a result of this transaction, CTP has changed its name to Neurologix, Inc. About Neurologix, Inc. Neurologix, Inc. (the "Company") is a development stage company, involved in developing treatments for disorders of the brain and central nervous system using gene therapy and other alternative therapies. The Company's initial development efforts are focused on gene therapy for treating Parkinson's disease and epilepsy and its core technology, which it refers to as "NLX (hardware, standard) NLX - A low-profile, low TCO motherboard design created jointly by Intel Corp., IBM, DEC and other PC vendors. In contrast to the traditional single-board design, NLX uses a riser card to carry PCI, ISA and AGP bus data (despite Intel's stated intent to rid PC ", is currently being tested in a Phase I human clinical trial, sponsored by the Company, to treat Parkinson's disease. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion